Drug intelligence / Profile preview

ICCOV

Development stage: Phase 2
Lead developer: Immuno Cure BioTech
Modality: Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular

Overview

ICCOV is a SARS-CoV-2 DNA vaccine developed by Immuno Cure Holding (HK) Limited. It is being evaluated in clinical trials as a booster dose for adults aged 18 to 75 years who have previously received two to four doses of COVID-19 vaccine, with the primary purpose of assessing its immunogenicity and safety.

Other names: SARS-CoV-2 DNA Vaccine (ICCOV)

Beyond the preview

Go deeper on ICCOV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICCOV.